W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conference
William and Anthony are chairing SMi's Superbugs & Superdrugs USA Conference and encourage all involved in AMR to join experts from multiple disciplines, in the field of infectious disease representing research, regulatory, funding, diagnostics and academia, at this event in New Jersey on November 12 -13, 2018.
Superbugs & Superdrugs USA Conference will become a platform where participants will get exposure to presentations and discussions focusing on supporting antimicrobial research and development, funding opportunities and resources for companies, new diagnostics for clinical applications, as well as novel therapies and approaches being undertaken for the future prevention and treatment of MDR infections.
Read on below the official letter from the chairs to participants, and reserve your ticket to attend SMi's Superbugs & Superdrugs USA Conference via http://www.superbugs-usa.com/openpr
In the last decade we have witnessed a dramatic increase in both the proportion and absolute number of bacterial pathogens exhibiting multidrug resistance to current antibacterial agents. Organizations such as the US Centers for Disease Control and Prevention (CDC), the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) are considering infections caused by multi-drug resistant (MDR) bacteria as an emergent global disease and a major public health problem.
This ‘antibiotic resistance crisis’ has been compounded by a lagging in investments in antibiotic discovery and development programs in recent years, particularly as made by large pharmaceutical companies.
The emergence of MDR resistant microorganisms, either by mutation or the acquisition of mobile genetic elements carrying resistance genes, is driven through inappropriate antibiotic use but also likely takes place irrespective of exposure to antimicrobial agents. Increasing collaboration among concerned stakeholders to establish policies, initiatives, and investments in new agents to battle the antibiotic resistance crisis is promising. However, while recently approved antibiotic agents will likely help stem this crisis, novel approaches to the prevention and treatment of MDR infections are needed to ensure a viable antimicrobial armamentarium for the future.
The 3rd SMI USA Superbugs & Superdrugs meeting will bring together expertise from individuals in multiple disciplines in the field of infectious disease representing research, regulatory, funding, diagnostics and academia.
We look forward to meeting you in New Jersey in November 2018!
William J. Weiss, Director of PreClinical Services, UNT System College of Pharmacy
A. Simon Lynch, Senior Scientific Director, Janssen Research & Development
Further details at http://www.superbugs-usa.com/openpr
Twitter - @SMIpharm & #smibugs
LinkedIn - SMi Pharma
+44 (0)20 7827 6000
Superbugs & Superdrugs USA Conference| November 12 – 13, 2018 | New Jersey
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.
1 Westminster Bridge Road
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release W. J. Wiess and A.S. Lynch invitation to SMi’s Superbugs & Superdrugs USA Conference here
News-ID: 1119703 • Views: 1073
More Releases from SMi Group
Only 6 weeks to go until The Transdermal and Microneedle Delivery Conference
SMi Reports: Time is running out to Register for SM’s inaugural conference: Transdermal and Microneedle Delivery will take place on 24th - 25th January 2022 SMi Group is proud to present the inaugural Transdermal and Microneedle Drug Delivery Conference, taking place on the 24th to 25th January 2022, in London, UK. The Conference will explore real world applications of microneedles in drug delivery and strategies for device design while engaging in
Only 6 weeks to go until the Pre-filled Syringes and Injectable Devices Conferen …
SMi Reports: Registration is open for SMi’s 14th Annual Conference and Exhibition taking place between 12th-13th January 2022 in London, UK. The pre-filled syringes industry is growing at an exponential rate with innovations in parenteral delivery device development to aid self-administration and deliver biologics, high concentration, and large-volume drug products. This year’s conference will explore the exciting advances in the combination product delivery space including insights into how the industry is
SMi Presents the 16th Annual Conference: Parallel Trade 2022
SMi Presents the 16th Annual Conference: Parallel Trade 2022 Conference Date: 21st – 22nd March 2022 Workshop date: 23rd March 2022 Website: www.parallel-trade.com/ Navigating the challenges and legal landscapes of parallel trade SMi presents its 16th annual Parallel Trade conference on the 21st and the 22nd March 2022. As the only parallel trade conference in Europe, this event provides the perfect platform for industry experts from both sides of the coin to come together
The Future of Transdermal and Microneedle Drug Delivery according to Ester Caffa …
SMi Reports: In preparation for the Inaugural Transdermal and Microneedle Drug Delivery Conference we hear from LEO Pharma Dr. Ester Caffarel-Salvador is a multidisciplinary scientist with a background in biotechnology and biochemistry. She was recognized by the MIT technology review with the Innovators under 35 award in 2019 and the Nova Talent award in 2021. As a postdoc in Professor Robert Langer's laboratory at MIT, she developed a novel pill design
More Releases for Superbugs
Interview with Martin Everett speaker at SMi's Superbugs & Superdrugs Conference
SMi Reports: An Interview with Martin Everett, Chief Scientific Officer, at Antabio, who will be speaking at SMi's highly anticipated 22nd Annual Superbugs & Superdrugs Conference on the 30th and 31st March 2020 in London. This year's global focused two-day conference pharmaceutical is for industry professionals looking to gain an in-depth knowledge of the scientific, economic, and regulatory challenges facing the critical global issue of antibiotic resistance. For interested individuals to attend
Four weeks until SMi’s 21st Annual Superbugs & Superdrugs Conference 2019
SMi Reports: Senior industry experts will gather in London to discuss the recent advances made in combating antibiotic resistance. As the global threat of antimicrobial resistance continues to grow, the advances of modern medicines are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. For this reason, the Superbugs & Superdrugs conference, taking
Registration Officially Opens for the 21st Annual Superbugs & Superdrugs Confere …
As the global threat of antimicrobial resistance continues to grow, the advances of modern medicine are at risk of being lost. Failure to act quickly means the spread of antibiotic-resistant bacteria could lead to increased mortality from normally minor injuries and benign infections. SMi’s highly anticipated Superbugs & Superdrugs conference is set to return to London, UK for its 21st year running, on the 18th & 19th March 2019 (http://www.superbugssuperdrugs.com/openpr). This
Superbugs & Superdrugs USA Conference returns to New Jersey this November
SMi Group reports: agenda released for 3rd annual Superbugs & Superdrugs USA conference Building on almost two decades worth of expertise in fighting the growing threat of antimicrobial resistance (AMR), SMi Group is pleased to announce the release of the official agenda for the 3rd annual Superbugs & Superdrugs USA Conference, which is due to take place in Iselin, New Jersey on November 12 - 13, 2018. Antimicrobial resistance, leading to the
Antibiotic Drug Experts + Senior Industry Leaders set to Gather at Superbugs USA
SMi Group will open doors in 3 weeks to host the next annual USA Superbugs summit when it returns to Iselin, New Jersey on Nov 13th – 14th. http://www.superbugs-usa.com/opr Following over two decades of expertise in Europe, the USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline and resistance prevention. Highlights will include
Motif Biosciences Unveil Novel Solutions for the Treatment Deadly Superbugs
SMi Group will welcome the expertise of David Huang when he presents exclusive updates on Iclaprim, a novel diaminopyrimidine, for the treatment of serious gram- positive infections, at Superbugs & Superdrugs USA this fall. The talk will explore how Iclaprim addresses an unmet medical need in hospitalized patients with serious and life-threatening infections including MRSA. With over 15 years of clinical, academic, industry, and research experience in medicine and in the